CRF1 and ACTH blockers (such as crinecerfont and atumelnant, respectively) may replace leptin action on the adrenal axis by reducing adrenal cortisol excess in individuals with obesity.<h4>Context</h4>Individuals with obesity experience a subtle hypercortisolism secondary to leptin resistance. This evidence concerns the gene POMC and obesity disorder.